The model was parametrized using experimental and clinical pharmacokinetic data to investigate potential combinations of the HAP evofosfamide with the targeted tyrosine kinase inhibitor erlotinib against EGFR-activated non small cell lung cancer. Here, EGFR is linked to non-small cell lung carcinoma.